Suboxone Generics Launched
February 22, 2019 – Alvogen, Mylan, and Dr. Reddy’s Laboratories have released generics for Indivior’s Suboxone® (buprenorphine/naloxone) sublingual film following the U.S. Supreme Court’s refusal to hear a patent case that could have delayed the generics’ entry into the market.
Dr. Reddy’s had previously launched Suboxone generics in June 2018, but was forced to withdraw them due to legal action.
Both Dr. Reddy’s and Alvogen have launched generics for all four strengths of Suboxone, while Mylan launched only generics for the two highest dosage strengths. Authorized generics in all four strengths are also available from Sandoz. Although pricing for most of the generics has not been announced, Sandoz’s generics have a wholesale acquisition cost (WAC) that is 14% lower than the brand equivalents.
Suboxone and its generics are Schedule III controlled substances indicated to treat opioid use disorder as part of a regimen that includes counseling and psychosocial support.